Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D-Leucine ((R)-Leucine) potently terminates seizures even after the onset of seizure activity. D-leucine reduces long-term potentiation but had no effect on basal synaptic transmission in vitro.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
500 mg | In stock | $ 41.00 |
Description | D-Leucine ((R)-Leucine) potently terminates seizures even after the onset of seizure activity. D-leucine reduces long-term potentiation but had no effect on basal synaptic transmission in vitro. |
In vitro | D-Leucine failed to compete for binding by cognate ligands in a screen of candidate neuronal receptors, potentially suggesting a novel target. D-Leucine suppressed ongoing seizures at least as effectively as diazepam even at low doses, but without sedative effects. These studies raise the possibility that D-Leucine may represent a new class of anti-seizure agents, and that D-Leucine may have a previously unknown function in eukaryotes[1]. |
Synonyms | (R)-Leucine |
Molecular Weight | 131.17 |
Formula | C6H13NO2 |
CAS No. | 328-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
D-Leucine 328-38-1 Metabolism Endogenous Metabolite Leucine inhibit DLeucine D Leucine Inhibitor (R)-Leucine inhibitor